Metformin hydrochloride is a classic first-line agent for the clinical management of type 2 diabetes mellitus. Owing to its stable hypoglycemic efficacy, low risk of hypoglycemia, and ability to ameliorate insulin resistance, it has gained widespread clinical application. The drug generally exhibits a favorable safety profile and is well-tolerated for long-term use in most patients. Nevertheless, adverse reactions of varying severity may still occur depending on individual physical constitution, dosage regimen, and administration method. Most adverse reactions are mild and reversible, and can be effectively relieved with appropriate medication adjustments. Although severe adverse reactions are rare, they require close vigilance. This article categorizes and elaborates on its principal adverse reactions to provide evidence for rational medication use.
I. Gastrointestinal Adverse Reactions (Most Common)
Gastrointestinal intolerance constitutes the most prevalent adverse reaction of metformin hydrochloride, usually developing within the first one to two weeks of treatment, and represents a leading cause of treatment discontinuation. These symptoms arise from high local drug concentrations in the gastrointestinal tract, mucosal irritation, and altered intestinal carbohydrate metabolism, manifesting as abdominal distension, diarrhea, nausea, vomiting, anorexia, dull epigastric pain, acid regurgitation and other complaints.
Such gastrointestinal side effects typically diminish with tolerance development. For most patients, the gastrointestinal tract gradually adapts to drug stimulation over time, leading to spontaneous alleviation or resolution of symptoms. Initiating treatment at a low dose and administering the medication with or immediately after meals can markedly reduce gastrointestinal irritation. Persistent severe diarrhea or vomiting warrants prompt medical review for regimen modification to prevent secondary complications such as dehydration and electrolyte disturbances. Clinical data indicate that standardized administration adjustment can lower the incidence of gastrointestinal adverse reactions from over 30% to below 10%.
II. Lactic Acidosis (Most Severe Rare Adverse Reaction)
Lactic acidosis is the most life-threatening adverse reaction associated with metformin hydrochloride, yet its incidence is extremely low, predominantly seen in patients with inappropriate dosing or underlying comorbidities. Metformin inhibits hepatic gluconeogenesis and impairs lactate breakdown; under physiological conditions, the human body can compensate normally to prevent abnormal lactate accumulation. However, in settings including renal insufficiency, severe infection, hypoxia, alcohol abuse, strenuous physical activity, or excessive metformin dosing, excessive lactate buildup may trigger acidosis.
Early manifestations of lactic acidosis include fatigue, myalgia, dizziness, drowsiness, and deep, rapid breathing with a fruity odor. Disease progression may result in nausea, vomiting, confusion, hypotension, coma and other critical presentations, which can be fatal without timely intervention. To mitigate this risk, metformin is contraindicated or used with extreme caution in patients with renal impairment, severe cardiopulmonary disease, chronic alcoholism or acute infection, and overdose is strictly prohibited during treatment.
III. Nutritional and Metabolic Adverse Reactions
Long-term metformin hydrochloride administration may interfere with intestinal absorption of vitamin B12, resulting in vitamin B12 deficiency. The drug hinders the uptake and utilization of vitamin B12 by intestinal mucosa, leading to progressively reduced serum vitamin B12 levels with prolonged treatment. Mild deficiency is often asymptomatic, whereas chronic severe deficiency may induce peripheral neuropathy characterized by numbness, hypoesthesia and weakness in extremities, accompanied by megaloblastic anemia in some cases.
Accordingly, diabetic patients on long-term metformin therapy are advised to undergo regular monitoring of serum vitamin B12 levels, increase dietary intake of vitamin B12-rich foods, or take oral nutritional supplements under physician guidance when necessary to avoid metabolic complications. In addition, mild weight loss is observed in a small subset of patients, which is a benign physiological outcome driven by improved insulin resistance and reduced fat accumulation.
IV. Cutaneous and Mild Systemic Adverse Reactions
A small proportion of patients develop cutaneous hypersensitivity reactions following administration, presenting as pruritus, erythema, rash, urticaria and other lesions with variable severity. Mild cutaneous allergies can be managed with symptomatic anti-allergic therapy, whereas extensive severe rash or angioedema requires immediate drug discontinuation and urgent medical consultation.
Furthermore, rare mild systemic complaints including dizziness, headache, fatigue and bitter taste may emerge mostly in the initial treatment phase. These symptoms are usually mild, do not interfere with daily activities, and resolve spontaneously as tolerance develops. No cases of severe hepatic or renal injury attributable to this drug have been documented clinically; conventional doses pose no hepatotoxic or nephrotoxic risks to patients with normal liver and kidney function.
V. Medication Summary and Safety Recommendations
Overall, adverse reactions to metformin hydrochloride are predominantly mild, reversible gastrointestinal disturbances, while severe adverse events remain uncommon, confirming its reliable safety profile. Patients should not be overly anxious about side effects, as arbitrary dose reduction or discontinuation may trigger glycemic fluctuations and disease exacerbation. Clinical administration should follow the principle of low-dose initiation, gradual dose titration and postprandial intake. Contraindicated populations should be excluded, and regular liver function, renal function and blood work monitoring are recommended to minimize adverse reaction risks. Persistent discomfort or abnormal symptoms during treatment require timely medical assessment for professional regimen adjustment.
